Philadelphia, PA – October 9, 2018: Frontida BioPharm, Inc. is pleased to announce that Dr. Ralph Landau has been appointed to the role of President of Frontida BioPharm, Inc. He will be responsible for the operations in both the United States and China .

Dr. Landau brings over 28 years of pharmaceutical experience in both the branded and generic sectors with a wealth of highly successful R&D, manufacturing and commercial experiences. His proven record of taking customer-centric pharmaceutical companies to the next level will significantly augment Frontida’s management team and guide the next steps of the company’s growth.

Previously, Dr. Landau led key functions at mid-to large scale pharma companies including Merck, Novartis, Fougera, and Sandoz. Dr. Landau also has significant experience with compliance initiatives, having remedied some considerable regulatory challenges during his career.

Frontida BioPharm Chairman, Dr. Song Li, states, “Dr. Landau’s vision is to grow the company by focusing on both our CDMO heritage and importantly, the potential our capabilities afford. In particular, Dr. Landau will place emphasis on leveraging our R&D skills and manufacturing capacities to develop strong business partnerships where we can share the true potential of commercializing FDA-approved therapies. The combination of his experience, knowledge, drive and culture-building skills make Dr. Landau an ideal fit for Frontida‘s next stages of growth.”

About Frontida:
Frontida BioPharm, Inc. is a dynamic specialty pharmaceutical company focused to develop and manufacture immediate and controlled-release products utilized in key primary and orphan therapeutic categories. Our name (the Greek word for “caring”) demonstrates our focus to form strong business partnerships, to identify the best solutions for efficient and targeted product development, and to positively impact the lives of patients through the high-quality products we manufacture. With facilities in Philadelphia, PA and Aurora, IL capable of producing and packaging over 3 billion tablets, capsules and specialty dosage forms and our experienced team, Frontida partners with leading pharmaceutical companies to deliver important healthcare products to the US market.

Frontida has also assembled a nimble R&D team with the skills, training and experience to develop targeted-release pharmaceuticals, utilizing numerous oral, injectable, and topically-delivered technologies. In our brief history, Frontida has launched seven commercial products and numerous clinical trial materials with our clients through our R&D and engineering efforts. Utilizing our talented team, Frontida will collaboratively develop the highest quality healthcare products, contribute to our community both individually and corporately, and strive for continual improvement as a pharmaceutical development and manufacturing organization.